Axogen Inc. (AXGN)
NASDAQ: AXGNHealth CareBiotechnology: Electromedical & Electrotherapeutic ApparatusUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
AXGN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.33B
- Forward P/E
- 79.03
- EPS (TTM)
- -$0.63
- Dividend yield
- None
- Ex-dividend date
- Jan 27, 2010
- 52-week range
- 26.92 – 59.72
- Day range
- 55.03 – 56.91
- Volume / Avg
- 875.45K / 1.57M
- Beta
- —
- Shares outstanding
- 59.73M
52-week range
AXGN stock today
Axogen (AXGN) closed at $55.75 on Nov 20, down 1.06% (-$0.60), versus the S&P 500's 3.70% decline. At this level, AXGN sits near the top of its 52-week range of $26.92 to $59.72: 6.6% below the high, set on Nov 11, 2026 and 107.1% above the low. AXGN is up 70.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 107.5%.
Axogen has posted a net loss over the last twelve months (EPS of -$0.63), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Axogen
Company profileAxogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue.
- Sector
- Health Care
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CEO
- Mr. Michael D. Dale
- Headquarters
- Alachua, FL
- Employees
- 622
- Website
- axogeninc.com
Financial highlights
Full financialsIn fiscal 2025, Axogen generated $225.2 million in revenue, up 20.2% from fiscal 2024, its 15th consecutive year of revenue growth. Axogen reported a net loss of $15.7 million, compared with a loss of $10.0 million a year earlier. Gross margin was 74.3% (down from 75.8%) and operating margin -3.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $225.21M | $187.34M | $159.01M | $138.58M | $127.36M |
| Growth | +20.21% | +17.81% | +14.74% | +8.81% | +13.41% |
| Net income | $-15.70M | $-9.96M | $-21.72M | $-28.95M | $-26.98M |
| EPS (diluted) | $-0.34 | $-0.23 | $-0.51 | $-0.69 | $-0.65 |
Analyst forecast
ForecastConsensus (11 analysts)
strong_buy
Avg. price target
$59.27+6.31%
- Strong buy 2
- Buy 9
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 28, 2026
- EPS actual vs est.
- $0.04 vs $-0.03
- Surprise
- +233.33%
Dividends
Dividend history- Annual dividend
- $0.00
- Last payment
- $1.00
- Ex-dividend date
- Jan 27, 2010
AXGN news
All AXGN news- AxoGen: 3 Key Takeaways for Long-Term InvestorsNasdaq
- Beat the Market the Zacks Way: Vera Bradley, Herc, Visa in FocusNasdaqAMT, V, WMT, MCK
- Axogen, Inc. Announces Decision to Move Forward with Prostate Market Launch and Highlights $754m TAMNasdaq
- Axogen, Inc. to Participate in Multiple Upcoming Investor ConferencesGlobeNewswire
- Axogen Consensus Price Target Raised 10.66% to $60.27NasdaqAXGN, DDS
- GMED vs. AXGN: Which Stock Should Value Investors Buy Now?NasdaqGMED, AXGN
- Noteworthy Wednesday Option Activity: SPCX, AXGN, GFLNasdaqAXGN, GFL, SUN
- Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%NasdaqAXGN, GMAB, KIDS, LUNG
Axogen peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TMDXTransMedics Group Inc. | 85.25 | -9.33% | $2.96B | vs AXGN |
| LIVNLivaNova PLC | 90.73 | -1.46% | $5.00B | vs AXGN |
| CNMDCONMED Corporation | 46.56 | +0.39% | $1.39B | vs AXGN |
| CBLLCeriBell Inc. | 27.39 | +6.37% | $1.06B | vs AXGN |
| INMDInMode Ltd. | 12.42 | -2.20% | $714.70M | vs AXGN |
| CVCapsoVision Inc. | 6.11 | -3.17% | $327.56M | vs AXGN |
| ELMDElectromed Inc. | 22.98 | -1.20% | $187.84M | vs AXGN |
| FOCLEDAP TMS S.A. ADR | 2.61 | -7.45% | $123.25M | vs AXGN |
Indexes, lists and sector
Axogen stock FAQ
What is Axogen's stock price today?
AXGN last traded at $55.75 as of Nov 20, 4:00 PM EST, down 1.06% on the day. Prices are delayed at least 15 minutes.
Does Axogen pay a dividend?
Yes. Axogen pays $0.00 per share annually. The most recent dividend of $1.00 had an ex-dividend date of Jan 27, 2010.
Who is Axogen's CEO?
Mr. Michael D. Dale is the chief executive officer of Axogen Inc., which has about 622 employees.
Has AXGN ever split its stock?
Yes. The most recent AXGN stock split was a 105-for-100 split on Jul 11, 1994, one of 3 splits on record.
What is the AXGN 52-week high?
The 52-week high for AXGN is $59.72 and the 52-week low is $26.92. The stock is currently 6.6% below its high.